$2.03
3.33% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$2.03
+0.49 31.82% 1M
+0.04 2.01% 6M
+0.76 59.84% YTD
-3.40 62.62% 1Y
-22.98 91.88% 5Y
-16.17 88.85% 10Y
-16.17 88.85% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.07 3.33%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $169.94m
Enterprise Value $3.55m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.10
P/S ratio (TTM) P/S ratio 4.74
P/B ratio (TTM) P/B ratio 2.72
Revenue growth (TTM) Revenue growth -48.36%
Revenue (TTM) Revenue $35.84m
EBIT (operating result TTM) EBIT $-207.24m
Free Cash Flow (TTM) Free Cash Flow $-215.28m
Cash position $220.96m
EPS (TTM) EPS $-3.04
P/E forward negative
P/S forward 10.62
EV/Sales forward 0.22
Short interest 10.78%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Editas Medicine, Inc. forecast:

6x Buy
38%
8x Hold
50%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
36 36
48% 48%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 66 66
0% 0%
184%
- Research and Development Expense 177 177
6% 6%
494%
-201 -201
12% 12%
-561%
- Depreciation and Amortization 6.32 6.32
7% 7%
18%
EBIT (Operating Income) EBIT -207 -207
12% 12%
-578%
Net Profit -251 -251
51% 51%
-701%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Neutral
GlobeNewsWire
about 4 hours ago
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.
Negative
The Motley Fool
18 days ago
Over the past few years, investors have moved away from somewhat speculative and unprofitable companies to put their money into safer, steadier investments. Editas Medicine (EDIT -4.01%), a gene-editing-focused clinical-stage biotech, is firmly in the speculative camp, which is why its shares are down by 97% since early 2021.
Positive
Seeking Alpha
23 days ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 246
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today